| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
|
N Engl J Med
|
2005
|
15.30
|
|
2
|
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
|
N Engl J Med
|
2002
|
8.86
|
|
3
|
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
|
N Engl J Med
|
2007
|
8.77
|
|
4
|
Single versus double autologous stem-cell transplantation for multiple myeloma.
|
N Engl J Med
|
2003
|
7.35
|
|
5
|
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
|
N Engl J Med
|
2012
|
5.80
|
|
6
|
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
|
Blood
|
2007
|
5.55
|
|
7
|
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
|
Blood
|
2002
|
5.38
|
|
8
|
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.
|
Blood
|
2006
|
4.61
|
|
9
|
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
|
Blood
|
2006
|
4.40
|
|
10
|
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
|
J Clin Oncol
|
2010
|
4.02
|
|
11
|
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.
|
Blood
|
2011
|
4.00
|
|
12
|
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
|
Blood
|
2007
|
3.66
|
|
13
|
Prognostic significance of copy-number alterations in multiple myeloma.
|
J Clin Oncol
|
2009
|
3.21
|
|
14
|
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
|
N Engl J Med
|
2014
|
2.99
|
|
15
|
Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.
|
Blood
|
2002
|
2.75
|
|
16
|
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
|
J Clin Oncol
|
2010
|
2.75
|
|
17
|
Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
|
J Clin Oncol
|
2009
|
2.49
|
|
18
|
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
|
J Clin Oncol
|
2008
|
2.45
|
|
19
|
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
|
Br J Haematol
|
2009
|
2.32
|
|
20
|
Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation.
|
Blood
|
2002
|
2.32
|
|
21
|
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
|
Blood
|
2011
|
2.06
|
|
22
|
Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.
|
Blood
|
2013
|
2.06
|
|
23
|
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
|
Haematologica
|
2007
|
2.03
|
|
24
|
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
|
Clin Cancer Res
|
2006
|
1.99
|
|
25
|
Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
|
Lancet Oncol
|
2013
|
1.99
|
|
26
|
Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy.
|
Blood
|
2002
|
1.87
|
|
27
|
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
|
J Clin Oncol
|
2012
|
1.85
|
|
28
|
Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.
|
J Clin Oncol
|
2013
|
1.80
|
|
29
|
A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.
|
N Engl J Med
|
2003
|
1.72
|
|
30
|
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.
|
Blood
|
2011
|
1.69
|
|
31
|
Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
|
J Clin Oncol
|
2009
|
1.69
|
|
32
|
Thalidomide for treatment of multiple myeloma: 10 years later.
|
Blood
|
2008
|
1.66
|
|
33
|
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
|
Cancer
|
2003
|
1.65
|
|
34
|
Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.
|
J Clin Oncol
|
2012
|
1.60
|
|
35
|
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
|
Br J Haematol
|
2008
|
1.52
|
|
36
|
Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
|
Blood
|
2010
|
1.51
|
|
37
|
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.
|
Eur J Haematol
|
2009
|
1.45
|
|
38
|
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.
|
Haematologica
|
2010
|
1.42
|
|
39
|
Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
|
Cancer Res
|
2012
|
1.38
|
|
40
|
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
|
Cancer
|
2005
|
1.32
|
|
41
|
IMWG consensus on maintenance therapy in multiple myeloma.
|
Blood
|
2012
|
1.29
|
|
42
|
Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial.
|
Blood
|
2010
|
1.26
|
|
43
|
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
|
Lancet Oncol
|
2010
|
1.23
|
|
44
|
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
|
Br J Haematol
|
2007
|
1.21
|
|
45
|
Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients.
|
Am J Hematol
|
2013
|
1.11
|
|
46
|
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
|
Clin Pharmacokinet
|
2012
|
1.06
|
|
47
|
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
|
Oncologist
|
2011
|
1.06
|
|
48
|
Current multiple myeloma treatment strategies with novel agents: a European perspective.
|
Oncologist
|
2010
|
1.04
|
|
49
|
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma.
|
Haematologica
|
2013
|
1.03
|
|
50
|
Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma.
|
Br J Haematol
|
2009
|
1.01
|
|
51
|
European perspective on multiple myeloma treatment strategies: update following recent congresses.
|
Oncologist
|
2012
|
0.98
|
|
52
|
Prognosis assessment of cardiac involvement in systemic AL amyloidosis by magnetic resonance imaging.
|
Am J Med
|
2010
|
0.98
|
|
53
|
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma.
|
J Clin Oncol
|
2002
|
0.97
|
|
54
|
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia.
|
Leuk Lymphoma
|
2008
|
0.94
|
|
55
|
Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study.
|
Blood
|
2011
|
0.92
|
|
56
|
Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
|
Cancer
|
2013
|
0.90
|
|
57
|
Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM).
|
Hematol J
|
2002
|
0.90
|
|
58
|
Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
|
Clin Cancer Res
|
2005
|
0.90
|
|
59
|
Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients.
|
Clin Cancer Res
|
2007
|
0.89
|
|
60
|
Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
|
Eur J Haematol
|
2007
|
0.88
|
|
61
|
IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.
|
Cancer
|
2014
|
0.87
|
|
62
|
HLA-G and lymphoproliferative disorders.
|
Semin Cancer Biol
|
2003
|
0.87
|
|
63
|
Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.
|
PLoS One
|
2013
|
0.86
|
|
64
|
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
|
Br J Haematol
|
2009
|
0.86
|
|
65
|
Frontline treatment of multiple myeloma in elderly patients.
|
Blood Rev
|
2008
|
0.85
|
|
66
|
MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs.
|
Thromb Haemost
|
2013
|
0.85
|
|
67
|
Irregular nuclear shape of bone marrow plasma cells defines a multiple myeloma subgroup related to hypodiploidy and to short survival.
|
Leuk Res
|
2005
|
0.84
|
|
68
|
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.
|
Haematologica
|
2011
|
0.84
|
|
69
|
Modeling of experts' divergent prior beliefs for a sequential phase III clinical trial.
|
Clin Trials
|
2013
|
0.84
|
|
70
|
The translocation t(4;14) can be present only in minor subclones in multiple myeloma.
|
Clin Cancer Res
|
2013
|
0.82
|
|
71
|
Prognostic value of PINI index in patients with multiple myeloma.
|
Eur J Haematol
|
2012
|
0.82
|
|
72
|
Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.
|
Recent Results Cancer Res
|
2011
|
0.81
|
|
73
|
Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.
|
Joint Bone Spine
|
2007
|
0.81
|
|
74
|
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.
|
Br J Haematol
|
2014
|
0.79
|
|
75
|
Stem-cell transplantation in multiple myeloma.
|
Best Pract Res Clin Haematol
|
2005
|
0.79
|
|
76
|
Front line treatment of elderly multiple myeloma in the era of novel agents.
|
Biologics
|
2009
|
0.78
|
|
77
|
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
|
Blood
|
2003
|
0.78
|
|
78
|
Prognostic value of urinary pyridinium crosslinks and their derivatives in multiple myeloma.
|
Ann Hematol
|
2004
|
0.76
|
|
79
|
Bendamustine is effective in T-cell prolymphocytic leukaemia.
|
Br J Haematol
|
2014
|
0.76
|
|
80
|
Abnormal cytogenetics and significant bone marrow plasmacytosis are predictive of early progression and short survival in patients with low tumor mass asymptomatic multiple myeloma.
|
Leuk Lymphoma
|
2004
|
0.76
|
|
81
|
Pomalidomide for multiple myeloma.
|
Expert Rev Hematol
|
2014
|
0.76
|
|
82
|
Memory loss during lenalidomide treatment: a report on two cases.
|
BMC Pharmacol Toxicol
|
2013
|
0.76
|
|
83
|
Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.
|
Eur J Haematol
|
2012
|
0.75
|
|
84
|
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.
|
Semin Hematol
|
2003
|
0.75
|
|
85
|
Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgens.
|
Ann Hematol
|
2006
|
0.75
|
|
86
|
Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study.
|
Leuk Lymphoma
|
2013
|
0.75
|
|
87
|
Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.
|
Expert Rev Hematol
|
2012
|
0.75
|
|
88
|
Evaluation of gemcitabine in relapsed or refractory multiple myeloma.
|
Haematologica
|
2004
|
0.75
|
|
89
|
Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma.
|
Br J Haematol
|
2005
|
0.75
|
|
90
|
Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective multicenter nonrandomized phase II study in 120 patients.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.75
|
|
91
|
Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
|
Haematologica
|
2005
|
0.75
|
|
92
|
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.
|
Leuk Lymphoma
|
2007
|
0.75
|
|
93
|
[Prognostic factors and new treatments of multiple myeloma].
|
Rev Prat
|
2006
|
0.75
|
|
94
|
Recent phase III trials in the frontline treatment of multiple myeloma: evaluating their impact on community practice.
|
Clin Adv Hematol Oncol
|
2008
|
0.75
|
|
95
|
Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia.
|
Eur J Haematol
|
2008
|
0.75
|